Overview of Carvidon - MR

Quick Facts

Property	Description
Active ingredient	Trimetazidine Dihydrochloride
Form	Modified-Release (MR) Tablet
Pharmacological class	Metabolic Agent / Cytoprotective Anti-Ischemic Drug
General purpose	Optimizing cardiac energy metabolism
Origin	Synthetic Compound

Carvidon - MR is a synthetic cardiovascular medicine that acts as a metabolic agent to support the heart muscle's function and energy balance, primarily addressing stress caused by oxygen deprivation. Its core component is the substance Trimetazidine Dihydrochloride, a prescription-only compound that is clinically recognized for its unique cytoprotective properties. This places the drug in the pharmacological class of anti-ischemic agents that work at the cellular level, offering a differentiation from traditional heart medicines.

Definition and Pharmacological Classification

Carvidon - MR is a single-ingredient, synthetic medicine defined by its Trimetazidine content, which is classified as belonging to the group of fatty acid oxidation inhibitors. The medicine is a cytoprotective anti-ischemic drug because its role is to modulate the heart cell's internal biochemistry rather than affecting the heart's mechanical or hemodynamic actions. This approach of stabilizing cellular energy processes is utilized during periods of metabolic stress.

Understanding the Modified-Release (MR) Tablet Form

This medicine is supplied for the oral administration route as a modified-release (MR) tablet, an oral solid formulation designed for sustained-release. The MR designation signifies that the Trimetazidine Dihydrochloride is formulated within a pharmaceutical matrix that controls its delivery, ensuring the active ingredient is released gradually over an extended period. This mechanism provides a constant level of therapeutic metabolic support throughout the day, a key differentiating factor in the treatment of chronic conditions.

General Purpose of the Metabolic Action

The general purpose of the drug’s metabolic action is to enhance the efficiency of the heart muscle’s fuel usage, thus improving its resilience to low oxygen levels, known as ischemia. Trimetazidine functions as a myocardial metabolism modulator by encouraging heart cells to favor the more oxygen-efficient burning of glucose over fatty acids. The drug is designed to enhance the heart muscle's capacity to manage oxygen supply limitations. This medicine supports the heart's function by improving its ability to use oxygen efficiently during periods of stress. This optimization effectively corrects the cellular energy balance, helping to preserve the integrity and function of cardiac cells.

Regulatory References

Trimetazidine - referral | European Medicines Agency (EMA)

What side effects are possible with Carvidon - MR?

Possible Side Effects and Safety Information

The official safety profile for Carvidon - MR (Trimetazidine Dihydrochloride) is organized by regulatory authorities based on the frequency of reported adverse reactions and the system organ class affected.

Adverse Reaction Classifications

Side effects are officially classified into frequency categories, ranging from common to those where the frequency is not known due to limited available data.

Frequency Category	System-Organ Class Examples
Common (1 to 10 users in 100)	Gastrointestinal (e.g., Nausea, Abdominal pain), Nervous System (e.g., Headache, Dizziness), General (e.g., Asthenia).
Uncommon (1 to 10 users in 1,000)	Vascular (e.g., Orthostatic Hypotension, Flushing), Cardiac (e.g., Palpitations, Tachycardia).
Rare (1 to 10 users in 10,000)	Blood and Lymphatic System (e.g., Agranulocytosis, Thrombocytopenia).
Not Known (Frequency cannot be estimated)	Parkinsonian Symptoms, Hepatitis, Angioedema, Gait disturbance, Agitation.

Serious Safety Considerations

The most clinically significant adverse reactions documented in regulatory documents include Parkinsonian Symptoms (such as tremor, rigidity, and gait instability) and Orthostatic Hypotension. Regulatory data indicates that Parkinsonian symptoms typically emerge during the early months of treatment but are usually reversible, often resolving within four months after discontinuing the medicine.

Safety Restrictions and Special Populations

Carvidon - MR is contraindicated by regulatory bodies in patients who have established Parkinson's disease or existing Parkinsonian symptoms. It is also contraindicated for individuals with severe renal impairment (Creatinine Clearance less than 30 mL/min). Caution is specifically noted for use in older adults and patients with moderate renal impairment, who may be at a greater risk of drug exposure due to reduced renal clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented presentation and required emergency actions for an overdose of Carvidon-MR (Trimetazidine Dihydrochloride), based strictly on regulatory labeling.

Overdose Scope	Official Regulatory Documentation
Documented Overdose Presentations	Information on the clinical manifestations of Trimetazidine overdose is officially documented as limited.
Physiological Systems Affected	The primary systems noted are the vascular system, leading to hypotension, and the cardiac system, which may present with palpitations and tachycardia.
Dose-Related Factors	Overdose is characterized by the ingestion of an excessive number of tablets. No specific toxic dose level is defined in the regulatory labeling.
Population-Specific Notes	No specific population-based considerations (e.g., in elderly or renally impaired patients) are explicitly detailed within the official overdose management sections.
Emergency Response Statements	Patients must contact a doctor or the nearest hospital Emergency Department immediately.
When Immediate Medical Help is Required	Immediate medical help is required upon the event of taking too many tablets (suspected overdose).

Overdose Management and Classifications

The manifestations described, particularly severe arterial hypotension, are classified as serious and necessitate immediate, mandated medical attention. The regulatory basis for this information is derived from EMA-aligned Summary of Product Characteristics (SmPC) documents.

Official Overdose Statements:

The official prescribing information confirms that information regarding the clinical signs of Trimetazidine overdose is limited.
Documented clinical manifestations that may present in overdose situations include Arterial Hypotension, Orthostatic Hypotension, Palpitations, and Tachycardia.
Treatment for an overdose must be symptomatic and supportive, as regulatory documents state that no specific antidote is known.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile of Carvidon-MR by potential cardiovascular instability and the limited available data. This profile strictly mandates that urgent medical attention must be sought immediately following any suspected overdose, with subsequent care focused on symptomatic stabilization.

Therapeutic Uses of Carvidon - MR

Symptom Management in Chronic Angina

Carvidon-MR (Trimetazidine Dihydrochloride) is commonly used for the symptomatic management of stable angina pectoris in adult patients, a chronic condition where recurrent chest discomfort is driven by reduced oxygen supply to the heart. The use is relevant in clinical settings marked by the recurring nature of the disease and is applied across domains where additional symptomatic support is needed.

The therapeutic benefit is to support relief from symptoms related to physical discomfort, which includes chest pain, pressure, and functional limitations. It helps address symptom clusters that may become intense or disruptive, such as the pressure or tightness that creates noticeable physiological strain. The symptomatic management plays a role in managing the frequency and intensity of angina attacks, offering relief that helps patients cope more steadily with these difficult episodes.

“Applied during phases where the patient experiences heightened discomfort upon exertion, it contributes to improved day-to-day comfort.”

The medication is commonly used across conditions characterized by periods of heightened symptoms that interfere with daily functioning. Symptomatic relief supports general well-being during symptomatic phases, which may assist with maintaining functional stability during physical effort.

Quick Fact: Management for Ischemic Symptoms
Primary Indication	Symptomatic management of stable angina pectoris
Symptom Focus	Symptom clusters related to physical discomfort and reduced effort tolerance
Use Context	Applied across domains where additional symptomatic support is needed (add-on therapy)

Regulatory References

European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Carvidon - MR (Trimetazidine Dihydrochloride) is officially authorized only for adult patients. Regulatory labeling defines strict population-based exclusions and restrictions for use, focusing on specific health conditions and physiological states.

Eligibility Status	Defined Population
Contraindicated	Patients with Parkinson disease or related movement disorders (including tremors and restless leg syndrome).
	Patients with severe renal impairment (creatinine clearance < 30 mL/min).
	Patients with known hypersensitivity to the active substance or any excipient.
Not Recommended	Children and adolescents below 18 years, as safety and efficacy have not been established in this age group.
	Pregnant women, where use is preferable to avoid due to lack of human data.
	Breastfeeding women, as a risk to the infant cannot be excluded.
Use with Caution	Elderly patients over 75 years, due to age-related changes in renal function.
	Patients with moderate renal impairment (creatinine clearance [30-60] mL/min).
	Patients predisposed to closed-angle glaucoma or those at risk of falls related to hypotension.

This regulatory profile strictly limits the medicine to non-excluded adults, emphasizing conditional use for specific age and organ function groups, while prohibiting use in several defined populations.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Carvidon - MR

Interaction scope

Medicinal product categories with documented interactions: None reported. The official regulatory profile is defined by the absence of formal interactions with specific medicinal product categories.

Specific interacting medicines (if explicitly listed): None listed. Regulatory documents do not explicitly list specific medicines or substance classes that cause pharmacokinetic or pharmacodynamic drug-drug interactions.

Mechanistic basis of interactions (only if stated in label): Not applicable. Regulatory documents state the absence of formal drug-drug interactions, including those based on CYP enzyme inhibition or induction, or specific transporter mechanisms.

Timing-based interaction rules (if applicable): None documented. No mandatory separation or spacing of doses is required for co-administration with other medicinal products.

Population-specific interaction notes (if applicable):

Total clearance of the active substance is directly correlated with the patient’s creatinine clearance.
Moderate renal impairment (CrCl 30 –60 mL/min) is noted for expected increased exposure to the active substance.
Elderly patients may exhibit an increased elimination half-life and altered exposure due to age-related decrease in renal function.

Interaction-related restrictions:

Use is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).
Use is contraindicated in patients with established Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Contraindicated (for specific patient groups/conditions); None documented (for drug-drug interactions).

Regulatory basis (EMA / FDA / etc.): Information is based on governmental regulatory sources.

Interaction-context constraints (as defined in official documents): Constraints are primarily population-dependent (renal clearance) and disease-dependent (movement disorders), leading to formal prohibitions.

Resulting interaction structure

Official interaction statements:

No formal drug–drug interactions have been reported in the official prescribing information for Trimetazidine Dihydrochloride.
The pharmacokinetic characteristics of the drug are formally documented as not influenced by meals (absence of a drug–food interaction).
The medicine is strictly contraindicated due to altered exposure risk in patients with severe renal impairment.
Functional prohibitions are mandated, with the medicine contraindicated in the presence of Parkinsonian symptoms or related movement disorders.

Connection to the overall interaction profile (2–4 sentences): The product’s official interaction profile, as defined by regulatory documents, is characterized by the absence of reported drug–drug, CYP-mediated, or transporter-based interactions. The documented constraints focus exclusively on the increased systemic exposure resulting from impaired renal clearance and the absolute prohibition of use in patient populations with functional movement disorders. Regulatory authorities structure the interaction profile around these specific, non-drug-drug prohibitions and population-dependent pharmacokinetic considerations.

Mechanism of Action

The Mechanism of Myocardial Energy Modulation

Carvidon - MR (Trimetazidine Dihydrochloride) functions as a metabolic agent by selectively inhibiting the mitochondrial enzyme Long-Chain 3-Ketoacyl Coenzyme A Thiolase (LC 3-KAT) within cardiomyocytes. This action interferes with the final step of the fatty acid beta-oxidation pathway, prompting a compulsory metabolic shift. The heart cell alters its energy substrate utilization, favoring glucose oxidation and glycolysis, a process that requires less oxygen for the generation of ATP.

This shift initiates a protective intracellular cascade. By limiting the production of hydrogen ions ( H^+), the mechanism prevents the damaging hyperactivation of the sodium-hydrogen exchanger. Consequently, this action results in the preservation of cellular ion homeostasis, stabilizing the internal concentrations of Na^+ and Ca^2+ ions, which maintains the cell's ability to undergo contraction.

This pharmacological action is categorized as cytoprotective, mitigating cellular damage through metabolic optimization and intrinsic anti-oxidant properties. The mechanism enhances myocardial efficiency and preserves cell viability, acting independent of changes in heart rate or blood pressure.

Dosage and Administration Information

General Administration and Dosing

This medicine is intended for oral administration as a 35 mg Modified-Release (MR) tablet. The standard regimen for adults is one 35 mg tablet taken twice daily—once in the morning and once in the evening—to achieve a total daily dose of 70 mg.

For proper use, the MR tablet must be swallowed whole and not chewed, crushed, or split, as this would disrupt the controlled release of the active ingredient. Both daily doses must be taken during meals to optimize drug absorption and consistency. If a dose is missed, it should not be doubled; the patient should simply take the next dose at the regular scheduled time. The treatment protocol requires a re-assessment of the drug's effect after three months of continuous use, and discontinuation is advised if no benefit is observed.

Population-Specific Use

Dosing requires adjustment based on kidney function. In adults with moderate renal impairment (creatinine clearance of 30–60 mL/min), the total daily dose is reduced to 35 mg once daily, taken in the morning during breakfast. Caution is advised when prescribing to older adults, and the reduced dose applies if this population also presents with moderate renal impairment. The use of this medicine is not recommended for the pediatric population (under 18 years) because safety and efficacy have not been formally established.

Recent Clinical Evidence

Carvidon - MR: Recent Clinical Evidence

Evidence for Symptom and Functional Management in Stable Angina

The core research base for Carvidon - MR was established in studies that examined the symptomatic management of stable angina pectoris. Most of the evidence is built upon short-term, randomized, double-blind, placebo-controlled trials (RCTs). These RCTs are synthesized by systematic reviews and meta-analyses, which pool the findings of multiple studies to identify consistent patterns in the data. These studies were generally applied in research contexts involving fluctuating or unstable symptoms, specifically in adults with stable angina who were already receiving established background anti-anginal treatments.

Research examined two main areas: changes in clinical symptom frequency and changes in functional capacity. Functional studies explored outcomes related to a patient’s daily functioning or activity level. Meta-analyses and individual studies reported measured changes in both symptomatic and functional outcomes when the medicine was compared against a placebo. Research describes measured differences during the short study periods, and regulatory reviews confirmed the medicine's indication for use as an add-on therapy in this context.

Follow-Up and Data on Sustained Outcomes

Research has monitored patient responses over defined time intervals, with the majority of the controlled trials reporting short-term outcomes over a period of up to three to six months. The durability of the measured symptomatic and functional outcomes over many years is not well characterized. The available evidence provides limited insight into outcomes over extended follow-up periods.

Evidence in Specific Adult Patient Groups

Studies explored the medicine’s evaluation in various adult study populations. Study populations included patients with co-existing conditions, such as Type 2 diabetes, and groups defined by the duration of their angina (from recently diagnosed to long-standing chronic disease). Evidence from observational studies in these settings describes patterns in how patients with different symptom burdens reported their experience. Results apply only to the populations studied, and data for certain complex groups remain insufficient.

Research Gaps and Limitations

The overall evidence landscape has several gaps and limitations that scientists have noted. One key limitation is that some of the older studies that initially established the medicine’s use were associated with methodological weaknesses. Follow-up durations were limited in the controlled trials, a research limitation for a medicine studied for a chronic condition. There is limited information for long-term outcomes related to major cardiovascular events. Comparative evidence is lacking for large, prospective trials that directly compare this medicine against other modern anti-anginal agents. The need for further research is acknowledged to address these questions and contribute to the broader evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Carvidon - MR (FAQ)

Q: Is Carvidon - MR a painkiller?

A: Official documents classify Carvidon - MR as an anti-ischemic metabolic agent. Its purpose is to help the heart muscle use energy more efficiently to increase its resilience to oxygen deprivation. This pharmacological action is distinct from the mechanism of traditional pain-relief medicines.

Q: Is Carvidon - MR a treatment for heart disease?

A: According to the official therapeutic indications, this medicine is indicated for the symptomatic management of stable angina pectoris in adults. Angina pectorus is a condition linked to coronary heart disease, and the medicine is used to manage its symptoms.

Q: How long does Carvidon - MR take to start working?

A: Official regulatory information indicates that the therapeutic benefit is observed over time. In clinical studies, measurable changes in physical capacity and clinical symptoms were typically noted after 8 to 12 weeks of continuous use.

Q: Is Carvidon - MR the same as metoprolol?

A: No. Carvidon - MR, which contains Trimetazidine, is a metabolic agent that works by changing how heart cells use energy. Medicines like metoprolol (a beta-blocker) work differently by affecting the heart's rate and rhythm. Official documents state this medicine is used as an add-on therapy alongside first-line treatments like beta-blockers.

Q: Is it normal to feel tired when first starting Carvidon - MR?

A: Feeling general weakness or lack of energy, which is officially termed Asthenia, is listed in regulatory documents as a common side effect. Since side effects often manifest when first starting a medicine, this is a known potential effect.

Q: Does Carvidon - MR affect blood pressure?

A: The drug’s main mechanism of action is focused on cellular metabolism and does not directly affect heart rate or blood pressure. However, official safety data lists low blood pressure upon standing, called Orthostatic Hypotension, as an uncommon side effect. Arterial Hypotension (low blood pressure) has also been reported as a rare event.

Q: Can you drink alcohol while taking Carvidon - MR?

A: Official regulatory information does not report a formal interaction between this medicine and alcohol. However, since the medicine may cause dizziness or orthostatic hypotension (low blood pressure upon standing), regulatory warnings note the need for awareness, as alcohol consumption could potentially amplify these effects.

Q: What happens if I stop taking Carvidon - MR suddenly?

A: The official prescribing information does not provide general instructions for stopping the medicine. In the specific case where movement disorders (like tremors or gait instability) develop, official guidance describes that treatment discontinuation is advised, and these symptoms are typically reversible within four months after withdrawal.

Q: Is Carvidon - MR an anticoagulant (blood thinner)?

A: No, Carvidon - MR is classified as a metabolic agent. Its purpose is to modulate how the heart cell uses energy by promoting glucose oxidation. This mechanism is distinct from the action of anticoagulants (blood thinners) and does not involve changing the clotting properties of blood.

Q: Does Carvidon - MR require a special diet?

A: Official product information does not require patients to follow a special restrictive diet while using this medicine. However, to ensure consistent drug exposure and absorption, regulatory documents specify that the tablet must be taken during meals.

Q: How long does the effect of one dose of Carvidon - MR last?

A: This is a Modified-Release (MR) formulation, designed to release the active substance gradually and provide sustained coverage throughout the day. The time it takes for half the drug to be eliminated from the body (half-life) is reported as approximately 7 hours in healthy young adults, and the corresponding dosing schedule is twice daily.

Q: Does Carvidon - MR interact with common herbal supplements?

A: Official regulatory information reports that no formal drug interactions have been identified or formally reported for the active substance. This general statement covers interactions with herbal supplements or other medicines.

Q: Can Carvidon - MR be taken with antacids?

A: Official regulatory documents state that no formal drug-drug interactions have been identified with this medicine. Therefore, no mandatory separation or spacing of doses is required when co-administering it with other products, such as antacids.

Q: Is Carvidon - MR a nitrate drug?

A: No, Carvidon - MR is not a nitrate drug. It belongs to the pharmacological class of metabolic agents, also known as fatty acid oxidation inhibitors. Its function is to optimize the heart's cellular energy use.

Q: Is it safe to drive after taking Carvidon - MR?

A: Official product information states that this medicine may cause side effects such as dizziness or drowsiness. Because these effects could potentially impair your ability to drive or operate machinery, caution is noted in the regulatory documents.

Q: How long do people typically stay on Carvidon - MR treatment?

A: Regulatory guidance requires that the benefit of the medicine be assessed after a continuous period of three months of use. If no benefit is observed at that point, discontinuation is advised.

Q: Does Carvidon - MR interact with cold and flu medications?

A: Official prescribing information reports that no formal drug-drug interactions have been identified for the active substance. This general statement covers interactions with other medicines, including common over-the-counter cold and flu preparations.

Q: Is Carvidon - MR listed as a controlled substance?

A: The active substance, Trimetazidine, is listed on the World Anti-Doping Agency (WADA) Prohibited List and may cause a positive result in doping tests for athletes. This classification relates to sports regulation and is separate from controlled substance classification for the general population.

Q: Does Carvidon - MR show up on drug tests?

A: Official warnings note that the active substance in this medicine is included on the World Anti-Doping Agency (WADA) Prohibited List. For this reason, it may cause a positive reaction in doping tests administered to athletes.

Q: Can I take ibuprofen with Carvidon - MR?

A: Official regulatory information reports that no formal drug-drug interactions have been identified or formally reported for this medicine. This includes common non-steroidal anti-inflammatory pain-relief medicines such as ibuprofen.

Q: What is the maximum amount of time Carvidon - MR remains in the body?

A: The time required for half of the medicine to be eliminated (the elimination half-life) is approximately 7 hours in healthy young adults. Official documents indicate that this half-life can increase to approximately 12 hours in patients over 65 years old.

Q: Does Carvidon - MR affect fertility?

A: Non-clinical studies conducted in animals have examined the potential effect of the active substance on fertility. The results of these studies did not indicate any harmful effects on the fertility of male or female animals.

Q: Is it okay to take Carvidon - MR with coffee or caffeine?

A: Official prescribing information states that no formal drug-drug interactions have been identified for the active substance. This general statement covers common beverages containing caffeine, such as coffee.

Q: What precautions are needed if I have liver disease and take Carvidon - MR?

A: Regulatory guidance for this medicine primarily focuses on kidney function, not liver function. However, Hepatitis, a type of liver inflammation, is listed as an adverse reaction with a frequency that cannot be estimated. Official safety warnings describe that symptoms such as yellowing of the skin and eyes should be reported immediately.

How should Carvidon - MR be stored and disposed of?

Official Storage and Disposal Requirements

Storage of Carvidon - MR (Trimetazidine Dihydrochloride Modified-Release) must follow specific regulatory conditions to maintain the product's quality.

Requirement Area	Labeled Mandate
Temperature	Store at a temperature below 30°C (86°F).
Protection	Must be protected from light and moisture.
Packaging	Keep the tablets in the original blister packaging.
Child Safety	Store out of the sight and reach of children.

Disposal Instructions

Unused or expired medication must be handled according to local requirements and environmental mandates. Regulatory documents state that the product must not be disposed of via wastewater or household waste. For appropriate disposal, unused tablets should be returned to a pharmacist or an official pharmaceutical waste collection point.

Carvidon - MR